Copeland M M
J Surg Oncol. 1977;9(1):2-14. doi: 10.1002/jso.2930090103.
Treatment for primary malignant tumors of bone, in the past several decades, has yielded uniformly poor results. Recent progress in chemotherapy and immunotherapy are detailed. An important advance in treating osteogenic sarcoma has been the application of adjuvant chemotherapy after initial amputation. CONPADRI-I and COMPADRI-II chemotherapy (a multiple drug approach) is discussed. Adriamycin in combination or alone has proved effective in treating osteogenic sarcoma. Ewing's tumor is showing increased survival rates from radiation therapy alone, as well as by use of systemic adjuvant chemotherapy combined with local radiation. Adjuvant triple chemotherapy with radiotherapy has resulted in pronounced improvement in survival. Chondrosarcomas are largely chemotherapy-resistant. Immunotherapy in bone tumors still is in the experimental stage and investigations with immunotherapy are preliminary. It appears, however, that the immunological status of a patient definitely relates to prognosis. Through increased sophistication in specific chemotherapy and magnitude of treatment, further advances in treatment of primary malignant bone tumors may be expected.
在过去几十年中，原发性骨恶性肿瘤的治疗效果一直很差。详细介绍了化疗和免疫疗法的最新进展。治疗骨肉瘤的一项重要进展是在初次截肢后应用辅助化疗。讨论了CONPADRI-I和COMPADRI-II化疗（一种多药联合方法）。阿霉素单独使用或联合使用已被证明对治疗骨肉瘤有效。尤因肉瘤仅通过放射治疗以及通过全身辅助化疗与局部放疗联合使用，生存率都有所提高。辅助三联化疗联合放疗已使生存率有显著提高。软骨肉瘤大多对化疗耐药。骨肿瘤的免疫疗法仍处于实验阶段，免疫疗法的研究尚属初步。然而，患者的免疫状态似乎确实与预后有关。随着特异性化疗的日益精细和治疗力度的加大，原发性恶性骨肿瘤的治疗有望取得进一步进展。
